Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

Erstveröffentlichung
2017
Authors
Staiger, Annette M.
Ziepert, Marita
Horn, Heike
Scott, David W.
Barth, Thomas F. E.
et al.
Wissenschaftlicher Artikel


Published in
Journal of Clinical Oncology ; 35 (2017), 22. - S. 2515+. - ISSN 0732-183X. - eISSN 1527-7755
Link to publication
https://dx.doi.org/10.1200/JCO.2016.70.3660
Institutions
UKU. Institut für Pathologie
Subject headings
[Free subject headings]: rituximab plus cyclophosphamide | paraffin-embedded tissue | chop consortium program | gene-expression | molecular subtypes | elderly-patients | phase-3 trial | myc status | predicts | survival
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item record